Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV plus docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC])

被引：0

作者：

Fumoleau, P.

Greil, R.

Rayson, D.

Mueller, V

Barni, S.

Aleknavicius, E.

Tellez, E.

Wilson, C.

Miles, D. W.

机构：

[1] Ctr Reg Lutte Canc, Dijon, France

[2] Med Univ Salzburg, Salzburg, Austria

[3] Dalhousie Univ, Halifax, NS, Canada

[4] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[5] Azienda Osped Treviglio Caravaggio, Treviglio, Italy

[6] Vilnius State Univ, Vilnius, Lithuania

[7] Inst Seguridad, Puebla, Mexico

[8] Serv Sociales Trabajadores Estado Puebla, Puebla, Mexico

[9] Addenbrookes Hosp, Cambridge, England

[10] Mt Vernon Canc Ctr, Mt Vernon, Middx, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：104S / 104S

页数：1